Besides targeting the mainly generic medicines market in the private and public sector and OTC markets worth about R25 billion, we will actively pursue growing opportunities in Africa. With regional regulatory harmonisation activities being supported and promoted actively by the African Union, this is becoming a serious opportunity to first movers and we will definitely be in the forefront of this development.

We have about 30 products in the MCC pipeline where we hope to receive registrations and marketing authorisations in the next year or two. The pipeline beyond that timeframe is also growing.

We have also acquired B-Pharm (Pty) Ltd. that also has about 15 products in the MCC pipeline that will further augment our product offering.

In the meantime, we have been offering our unique position and networks in South Africa to give assistance to the Japanese company to assist with their own efforts in the markets of Sub Saharan Africa. This is currently the only revenue we have. With our efforts as detailed above, we do however hope to be commercially active in the sales of pharmaceuticals by quarter 4 of 2017.

We have already initiated discussions with various companies to register and supply our products in Nigeria and Kenya, and once supply starts will be able to leverage the volumes to supply many other African countries. This will generate much needed export revenue for South Africa.

Since October 2016, we have initiated the regulatory changes as required by the MCC to update the dossier information so as to be able to launch the products under the new company name. These updates are still in progress. We expect the first product to be approved soon and have planned the product launch for August 2017.
We have a second product that we hope to supply on State tender after October 2017.

Our Products

Alendronate 70 Oethmaan

IV Antibiotic

Medreich Flucloxacillin
Oral antibiotic

Sutherlandia tablets
A blood-purifier or all-purpose tonic, treats chronic fatigue states, an anti-depressant, and a remedy for stomach problems and cancers.

Citalopram 20 Oethmaan

IV Antibiotic

For the treatment of urinary tract infections including cystitis

For symptomatic relief from cystitis and candida (oral, oesophageal and vaginal thrush) as well as all kinds of fungal, bacterial (including Escherichia coli), parasitic and protozoal infections.

Sulpiride 50 Oethmaan

IV Antibiotic

Sutherlandia gel
An antiseptic with anti-inflammatory, anti-oxidant, anti-bacterial and analgesic properties.

(paracetamol plus Codeine) – Analgesic


With the transition from being a subsidiary of a multinational pharmaceutical company to a fully black owned local pharmaceutical company, it is literally starting from scratch – with new products, new suppliers and even new customers. We, however, remain confident that with radical economic transformation firmly on the national agenda and the building blocks we have put in place, we are ready for the challenge in augmenting government’s objective of providing affordable and accessible medicines to all in South Africa.